Uncategorized

Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans.

Schilling JC, Adamus WS, Palluk R.

Human Pharmacology Centre, Boehringer Ingelheim KG, Germany.

The effects and tolerability of pramipexole, a new dopamine D2-receptor agonist, on prolactin, human growth hormone, thyrotropin, cortisol, and corticotropin levels were investigated in a randomized, double-blind, crossover study in 12 healthy volunteers. Single ...